BioSpace released a whitepaper on Apr. 15 that examines significant changes underway in the contract development and manufacturing organization (CDMO) sector, which serves as a key part of the pharmaceutical and biotechnology industries.
The report addresses why understanding these changes is important for companies looking to develop and manufacture drugs efficiently. As the market grows, driven by demand for comprehensive drug development services and closer collaboration between sponsors and outsourced providers, companies are seeking specialized partnerships with CDMOs.
According to BioSpace, advances in biologics, complex molecules, and cell and gene therapies have contributed to this trend. The whitepaper also discusses how U.S. economic policies promoting domestic manufacturing, as well as the adoption of artificial intelligence (AI), automation in CDMO processes, and evolving guidance from the Food and Drug Administration (FDA), are influencing decisions about where CDMOs operate and what services they offer.
The document outlines factors that pharmaceutical and biotech firms should consider when selecting a CDMO partner. It highlights that there are now more considerations than just raw production capacity when making these choices.
The whitepaper aims to help industry stakeholders understand both macroeconomic forces and technical developments shaping their options for outsourcing drug development work.
